Drug Profile
Sirolimus polymeric nanoparticle - Samyang
Alternative Names: PNP-sirolimus; Sirolimus PNPLatest Information Update: 21 Mar 2023
Price :
$50
*
At a glance
- Originator Samyang Biopharmaceuticals Corporation
- Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lactones; Macrolides; Nootropics; Polyenes; Pyridines; Skin disorder therapies
- Mechanism of Action Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 21 Mar 2023 Discontinued - Preclinical for Cancer in South Korea (IV)
- 17 Jan 2019 Sirolimus polymeric nanoparticle is still in preclinical trials for Cancer in South Korea (Samyang Biopharmaceuticals pipeline, January 2019)
- 01 Aug 2012 Nanopolymer sirolimus is available for licensing worldwide as of 01 Aug 2012. http://www.samyangbiopharm.com